Cormorant Asset Management, LP

October 16, 2026

Bright Minds Biosciences Gains Attention from Wolfe Research. Wolfe Research has started coverage of Bright Minds Biosciences, giving it an outperform rating and a price target of $150. The coverage comes as a Canadian biotech stock that is trading significantly below its fair value, up to 93% below, according to a recent Yahoo report. The new rating highlights the company’s potential relative to its peers. Investors are noting the price target in the context of the stock’s 52‑week range of $68.02 to $170.00.

September 30, 2026

Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.

October 16, 2026

Yahoo article highlights EYPT as a potential portfolio addition. A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.

September 28, 2026

RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.

September 26, 2026

BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.

September 27, 2026

Immuneering to Present Data at ESMO Congress 2026. Immuneering announced it will present data at the upcoming ESMO Congress in 2026. This event is relevant as it provides a future opportunity for the company to share clinical updates with the medical community. The stock is currently trading below its 52-week high, with analysts maintaining a wide range of price targets.

September 30, 2026

Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.

October 15, 2026

Tyra Biosciences (TYRA) Faces Turnaround After 27% Drop. Tyra Biosciences stock has fallen 27% over the past four weeks, a decline that has pushed the price near key support levels. Some market observers suggest this drop may signal a potential turnaround for the company. The average analyst target price remains significantly higher than the current trading range, reflecting a gap between current sentiment and long-term expectations.